Vatalanib (Standard)
Vatalanib (Standard) is the analytical standard of Vatalanib (HY-10203). This product is intended for research and analytical applications. Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 212141-54-3
- 分子式: C20H15ClN4
- 分子量:346.81
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
化学情報
- 純度とドキュメンテーション
-
Help & FAQs
-
HY-10981
LenvatinibVEGFR/FGFR Inhibitor -
HY-10203
VatalanibVEGFR2/KDR Inhibitor -
HY-10977
TivozanibVEGFR inhibitor -
HY-10260
VandetanibVEGFR2/3 Inhibitor -
HY-10205
CediranibVEGFR2 Inhibitor -
HY-10338
ForetinibMET/VEGFR2/KDR Inhibitor -
HY-10799
EG00229 trifluoroacetateNRP1 Receptor Antagonist -
HY-15458
SAR131675VEGFR3 Inhibitor -
HY-10065
AxitinibTyrosine Kinase Inhibitor -
HY-12018
Vatalanib dihydrochlorideVEGFR2/KDR Inhibitor -
HY-10407
SU 5402Tyrosine Kinase Inhibitor
Product Information
説明
アプリケーション
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
化学情報
-
CAS 番号 212141-54-3
-
分子量 346.81
-
分子式 C20H15ClN4
-
SMILES
ClC1=CC=C(C=C1)NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4
-
別名
PTK787 (Standard); ZK-222584 (Standard); CGP-79787 (Standard)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8 [Content Brief]
[2]. Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011, 18(2), 589-596. [Content Brief]
[3]. Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016 Mar;35(3):1297-308. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Vatalanib (Standard) 関連分類
HY-10203R 関連分類
Powered by Bioz